Ledipasvir

Ledipasvir is a benzimidazole derivative that is used in combination with sofosbuvir for the treatment of chronic hepatitis C genotype 1 infection. Among its listed roles, it functions as a antiviral drug and a hepatitis C protease inhibitor. It is a carbamate ester, a L-valine derivative, a bridged compound, a carboxamide, a benzimidazole, a member of fluorenes, an organofluorine compound, a member of imidazoles, a N-acylpyrrolidine and an azaspiro compound. Its therapeutic use is listed as anti-infectives and antivirals. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Ledipasvirum and Ledipasvir Acetonate. Its PubChem CID is 67505836.

CAS No 1256388-51-8
Molecular Formula C49H54F2N8O6
Molecular Weight 889.00 g/mol
Synonyms methyl N-[(2S)-1-[(6S)-6-[5-[9,9-difluoro-7-[2-[(1R,3S,4S)-2-[(2S)-2-(methoxycarbonylamino)-3-methylbutanoyl]-2-azabicyclo[2.2.1]heptan-3-yl]-3H-benzimidazol-5-yl]fluoren-2-yl]-1H-imidazol-2-yl]-5-azaspiro[2.4]heptan-5-yl]-3-methyl-1-oxobutan-2-yl]carbamate

Frequently Asked Questions